University Medical Center Freiburg

EQS-News: PRECISIS GmbH: EASEE – ­­­World's first minimally invasive brain pacemaker for the treatment of epilepsy receives CE-certification and is available immediately

Retrieved on: 
Friday, September 23, 2022

Heidelberg, 23.09.2022 after seven years of development work, Precisis GmbH, headquartered in Heidelberg, has received the CE certification for its minimally invasive brain pacemaker EASEE.

Key Points: 
  • Heidelberg, 23.09.2022 after seven years of development work, Precisis GmbH, headquartered in Heidelberg, has received the CE certification for its minimally invasive brain pacemaker EASEE.
  • These drug-refractory patients wait an average of 22 years before they are offered further technical or surgical treatment options.
  • With this new, risk-minimized EASEE method, the treatment spectrum is expanded in the early phases of the disease."
  • EASEE is an acronym for Epicranial Application of Stimulation Electrodes for Epilepsy.

Universal Medical (2666.HK) Announces 2022 Interim Results

Retrieved on: 
Wednesday, August 31, 2022

- Pursuing Progress in Revenue, Increased by 14.1%

Key Points: 
  • - Pursuing Progress in Revenue, Increased by 14.1%
    HONG KONG, Aug 31, 2022 - (ACN Newswire) - The board of directors of Genertec Universal Medical Group Co Ltd (the "Company" or "Universal Medical"; Stock code: 2666.HK) is pleased to announce the interim results of the Company and its subsidiaries (together, the "Group") for the six months ended 30 June 2022.
  • Genertec Universal Medical Group Co., Ltd. ("Universal Medical"; 2666.HK) is a publicly listed state-owned enterprise committed to China's healthcare industry.
  • Universal Medical focuses on the fast-developing healthcare industry in China, with medical services as the core and financial business as the foundation.
  • This press release is released by PEANUT MEDIA LIMITED on behalf of Genertec Universal Medical Group Company Limited.

Zymo Research's DNA/RNA Shield™ Inactivates Monkeypox for the Collection and Transportation of Samples

Retrieved on: 
Thursday, July 14, 2022

This data comes at a critical time as Monkeypox cases continue to climb worldwide and scientists are seeking methods to safely collect and transport samples without compromising the genetic integrity.

Key Points: 
  • This data comes at a critical time as Monkeypox cases continue to climb worldwide and scientists are seeking methods to safely collect and transport samples without compromising the genetic integrity.
  • The DNA/RNA Shield product line includes sample collection, preservation, and transportation devices for specimens used in research and infectious disease testing workflows.
  • DNA/RNA Shield has enabled researchers to conduct infectious disease research and testing over the past decade, including throughout the COVID-19 pandemic.
  • Zymo Research offers several devices that can be filled with DNA/RNA Shield, including the popular SafeCollect Swab Collection Kit.

Zymo Research's DNA/RNA Shield™ Inactivates Monkeypox for the Collection and Transportation of Samples

Retrieved on: 
Thursday, July 14, 2022

This data comes at a critical time as Monkeypox cases continue to climb worldwide and scientists are seeking methods to safely collect and transport samples without compromising the genetic integrity.

Key Points: 
  • This data comes at a critical time as Monkeypox cases continue to climb worldwide and scientists are seeking methods to safely collect and transport samples without compromising the genetic integrity.
  • The DNA/RNA Shield product line includes sample collection, preservation, and transportation devices for specimens used in research and infectious disease testing workflows.
  • DNA/RNA Shield has enabled researchers to conduct infectious disease research and testing over the past decade, including throughout the COVID-19 pandemic.
  • Zymo Research offers several devices that can be filled with DNA/RNA Shield, including the popular SafeCollect Swab Collection Kit.

Universal Medical Announces 2021 Annual Results: Business with Steady Promotion, Net Profit of Hospital Group Increased by 39.5%

Retrieved on: 
Tuesday, March 29, 2022

-- For the year ended 31 December 2021, the return on equity was 15.37%, and the return on total assets was 3.09%.

Key Points: 
  • -- For the year ended 31 December 2021, the return on equity was 15.37%, and the return on total assets was 3.09%.
  • Genertec Universal Medical Group Co., Ltd ("Universal Medical") is a publicly listed state-owned enterprise committed to China's healthcare industry.
  • Universal Medical focuses on the fast-developing healthcare industry in China, with medical services as the core and financial business as the foundation.
  • This press release is released by PEANUT MEDIA LIMITED on behalf of Genertec Universal Medical Group Company Limited.

VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease

Retrieved on: 
Wednesday, October 20, 2021

BASEL, Switzerland, Oct. 20, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to evaluate apraglutide, a next-generation, long-acting GLP-2 analog, in a Phase 2 clinical trial called STARGAZE (Study of Apraglutide in Graft-Versus-Host Disease), for the treatment of steroid-refractory acute graft-versus-host disease (aGVHD).

Key Points: 
  • We have demonstrated promising preclinical results with apraglutide as a novel approach to treating acute graft-versus-host disease, showing a significant reduction in mortality after treatment with apraglutide in mouse models.
  • STARGAZE, a Phase 2, randomized, double-blind study, will assess the safety, tolerability, pharmacokinetic profile and efficacy of apraglutide in patients with steroid-refractory aGVHD.
  • Apraglutide is also being evaluated in steroid-refractory acute graft-versus-host disease (aGVHD) and has demonstrated improvements in survival in pre-clinical aGVHD models.
  • It is being developed for a range of rare gastrointestinal diseases where GLP-2 plays a central role in disease pathophysiology, including Acute Graft-Versus-Host Disease (aGVHD).

Fluidigm 2021 IMC Summit Focuses on ‘Uncovering Spatial Biology’

Retrieved on: 
Monday, October 18, 2021

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the agenda for its IMC Summit: Uncovering Spatial Biology.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the agenda for its IMC Summit: Uncovering Spatial Biology.
  • The October 21 virtual event highlights research insights attained by deciphering and uncovering the complex secrets of spatial biology using Imaging Mass Cytometry (IMC).
  • During the Summit, Fluidigm will introduce Maxpar OnDemand Antibodies, an expanded option that more than doubles the current catalog offering for metal-conjugated antibodies for IMC.
  • Fluidigm, the Fluidigm logo, CyTOF, Hyperion, Imaging Mass Cytometry, IMC, and Maxpar are trademarks and/or registered trademarks of Fluidigm Corporation or its affiliates in the United States and/or other countries.

VectivBio Announces Upcoming Investor Events

Retrieved on: 
Thursday, September 16, 2021

BASEL, Switzerland, Sept. 16, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announcedupcoming investor events.

Key Points: 
  • BASEL, Switzerland, Sept. 16, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announcedupcoming investor events.
  • VectivBio will host a virtual R&D Day for analysts and investors on Tuesday, September 21, from 10 a.m. 12 p.m. EDT.
  • The webcast can be accessed in the Events & Presentations section of VectivBios website at https://ir.vectivbio.com/events-and-presentations and registration is now open.
  • Except to the extent required by law, VectivBio undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

VectivBio to Acquire Comet Therapeutics and Host R&D Day

Retrieved on: 
Tuesday, August 31, 2021

BASEL, Switzerland, Aug. 31, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that it will acquire Comet Therapeutics, Inc., a privately held company that has been developing drugs to address previously untreatable Inherited Metabolic Diseases. This acquisition significantly expands VectivBio’s rare disease pipeline.

Key Points: 
  • - VectivBio to Host R&D Day on September 21, 2021-
    BASEL, Switzerland, Aug. 31, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that it will acquire Comet Therapeutics, Inc., a privately held company that has been developing drugs to address previously untreatable Inherited Metabolic Diseases.
  • Under the terms of the agreement, VectivBio will acquire Comet Therapeutics in exchange for equity and cash payable at closing, as well as additional equity or cash payments upon the achievement of certain specified future development milestones.
  • Comet Therapeutics current investors include Sofinnova Partners, INKEF Capital, Canaan and Mission BioCapital.
  • VectivBio to Host R&D Day on September 21, 2021
    VectivBio will host an R&D Day for investors and analysts on Tuesday, September 21, 2021.

Universal Medical Announces 2021 Interim Results

Retrieved on: 
Friday, August 27, 2021

HONG KONG, Aug 27, 2021 - (ACN Newswire) - The board (the "Board") of directors (the "Directors") of Genertec Universal Medical Group Company Limited (the "Company" or "Universal Medical"; Stock code: 2666.HK) is pleased to announce the unaudited interim results of the Company and its subsidiaries (together, the "Group") for the six months ended 30 June 2021 (the "Reporting Period").

Key Points: 
  • HONG KONG, Aug 27, 2021 - (ACN Newswire) - The board (the "Board") of directors (the "Directors") of Genertec Universal Medical Group Company Limited (the "Company" or "Universal Medical"; Stock code: 2666.HK) is pleased to announce the unaudited interim results of the Company and its subsidiaries (together, the "Group") for the six months ended 30 June 2021 (the "Reporting Period").
  • Genertec Universal Medical Group Co., Ltd ("Universal Medical") is a publicly listed state-owned enterprise committed to China's healthcare industry.
  • Universal Medical focuses on the fast-developing healthcare industry in China, with medical services as the core and financial business as the foundation.
  • This press release is issued by ICA Investor Relations (Asia) Limited on behalf of Genertec Universal Medical Group Company Limited.